Press Release Archive
TOKYO and NEW YORK,February 11, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.
University of Louisville Named First Center of Excellence
Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer’s quality manufacturing standards and supply chain excellence
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 3:30 p.m. Pacific Standard Time.
- At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care
- BAVENCIO is the first immunotherapy to significantly prolong OS in locally advanced or metastatic urothelial carcinoma (UC) in the first-line setting in a Phase III trial
Rockland, MA and New York, US, January 6, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc.
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.